



INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL
SCIENCES & TECHNOLOGY

e-ISSN:2455-5134; p-ISSN: 2455-9059

OSTEOPOROSIS: REVIEW OF TREATMENT MODALITIES

Eman Abdullah, Marwan M. Merkhan, Zeina A. Althanoon

Department of Pharmacology and Toxicology
College of Pharmacy, University of Mosul, Iraq


Paper Received: 24th July, 2021; **Paper Accepted:** 08th September, 2021;

Paper Published: 08th September, 2021

DOI: <http://doi.org/10.37648/ijrmst.v11i02.003>

How to cite the article:

Eman Abdullah, Marwan M. Merkhan,
Zeina A. Althanoon, Osteoporosis:
Review of Treatment Modalities,
IJRMST, July-December 2021, Vol 12,
34-46, DOI:
<http://doi.org/10.37648/ijrmst.v11i02.003>



ABSTRACT

Proficient treatments are accessible for the management of osteoporotic diseases. Anti-resorptive remedies, comprising bisphosphonates and denosumab, increment bone mineral density (BMD) and diminish the hazard of breaks by 20–70%. Bone-mineralisation or bimodal-efficacy of medication invigorate bone arrangement and increment BMD more than the antiresorptive treatments. A couple of investigations have illustrated that these medicines are preferred over anti-resorptive in avoiding breaks in patients with serious osteoporosis. Bone-enhancing or bimodal-action medicines ought to be taken after by anti-resorptive remedies to keep up the break chance diminishment. The BMD picks up realised with bone-enhancing and bimodal-combat medicines are more prominent in medication-free patients compared to patients previously exposed to anti-resorptive medicines. Nonetheless, the anti-fracture efficacy seems to be protected. Treatment disappointment will frequently lead to a reversal of medication from orally to systemically taken anti-resorptive medications or from antiresorptive to bone-forming. Osteoporosis could be an incessant condition and hence needs prolonged therapy to arrange with an individualisation approach of therapy.

Keywords: *Calcium, Resorption, Bone, Osteoporosis, Osteogenesis.*

INTRODUCTION

Osteoporosis is a multifactorial disorder peculiarized by low bone density, weakened bone structure, and brittleness fractures. Osteoporosis influences > 200 million individuals globally. Osteoporotic breaks are linked to a high incidence of disability and mortality especially in the case of spinal or pelvic fractures. Bone turnover is the method by which the skeleton is remodelled and rebuild. It is a well-organized mechanism that involves

osteoclasts resorbing aged bone and then fortifying osteoblasts to make collagen and create modern bone. The actions of osteoclasts and osteoblasts are coordinated in terms of location and time during turnover.[1].

However, bone turnover started during skeleton development and growth and continue until adulthood and is capable of the continuous development of bone during adulthood and elderly lifetime.

Amid turnover, the lining cells on naive surfaces (of cortical and trabecular), are changed into osteoblasts, nonetheless, the balance between osteoclasts/osteoblasts isn't essentially integrated. Hence, bone generation can be either rebuild or deranged based on the remodelling process.

Osteoporotic breaks can be avoided by drug therapy. The currently accessible osteoporosis medicines are anti-resorptive (preventing osteoclasts), bone shaping (invigorating the osteoblasts) or bimodal acting (at the same time fortifying the osteoblasts and hindering the osteoclasts).

The antiresorptive medications are bisphosphonates, RANKL antibody and SERMs. Parathyroid hormone [PTH], amino acids 1–34 (**Teriparatide** and **abaloparatide**) are bone-generating medicines. **Romozosumab** A bimodal-acting treatment that activates bone generation and prevents bone degeneration[2].

The antiresorptive and bone-mineralisation medicines have one important property include; bone mineral resorption and arrangement as part of bone renovating stay stacked. However, clinically this therapy is not ideal. The bone resorption inhibition can boost bone mineral density (BMD) to a definite degree as the diminish

in osteoclast volume and dissolution of bone milieu and hence impede the accumulation of osteoblasts and endogenous biosynthesis of bone materials by osteoblasts³.

The bone mineral thickness increment observed with antiresorptive medications is in this manner caused by a filling of the building hole and accompanied by expanded mineralization of the osteogenic tissue as typically not renovated as regularly as some time recently starts of the treatment[1]. The bone engineering will not for the most part be improved, but the volume of cortical bone and bone quality as assessed and show better prognosis with zoledronate and denosumab. The osteoclasts are in this way fortified which decrease the impact of the therapy. Moreover, the reaction of the osteoblasts to preceded incitement decreased per unit time.

Hence, a few patients with exceptionally bone mass or trifling retort to bone-mineralisation therapy still have exceptionally bone mineralisation density after therapy[3].

As some reports have inspected on the off chance that the joining of bone resorption and arrangement can be conquered by re-joining the treatments. The bimodal-efficient therapy (romozosumab,

increasingly unhitch bone degeneration /regeneration).

The available threat is that in spite of the fact that the hindrance of bone degeneration stays throughout the therapy duration, the incitement of osteogenesis wears off despite proceeded management.

The recent survey will centre on the osteoporosis remedies accessible and how refined utilization of these treatments may offer assistance conquer the as of now lapsed needs within the treatment of osteoporosis[4].

ANTI-RESTORPTIVE MEDICATIONS

Bisphosphonates mechanism of action is based on their ability to influence osteoclast maintenance and action by restraining the mevalonate signalling pathway. Bisphosphonate therapy reduces bone resorption by up to 70%, lean on the bisphosphonate, and therefore reduces bone growth. This leads to increases in bone mass thickness at the spinal and pelvic levels over the first 3–4 years of therapy. From there on, the bone mineral thickness increment is preserved with no further increase. The lessening in bone resorption and elevation in bone osteogenic thickness lead to therapeutically significant diminutions in bone fracture risk. A later structured big

data analysis claimed that management of females with essential osteoporosis for few years with biphosphonates brought about in decreasing within the hazard of vertebral breaks by 43% (alendronate), 39% (risendronate), 33% (ibandronate) and 62% (zoledronate), separately [5].

Biphosphonates' effects have also been studied in individuals with steroid-induced osteoporosis. Both alendronate and risedronate's bone-breaking actions were studied in contrast to control placebo, and both medications were shown to recuperate bone mineral density and impede vertebral fractures. In a study comparing ibandronate to alfacalcidol, it was discovered that ibandronate increases bone mass thickness and diminutives vertebral fractures. Finally, utilizing risedronate as a comparator, the influence of zoledronate in medically sick patients with steroid-initiated osteoporosis was demonstrated. Zoledronate moved forward bone-mineral composition essentially higher than risedronate. The impact of prolonged use of bisphosphonates has primarily been explored within the expansions of the essential bone fracture investigation of alendronate and zoledronate. The fracture restraint studies indicate that biphosphonate plays a great role in the restriction of osteoporosis. The expansion reports included a defined

number of patients, and so, the factual influence to identify contrasts in breaks, particularly non-vertebral fractures, was constrained[6].

New research of females who took alendronate after a few years found that they had an enduring escalation in lumbar spine-bone mineralisation thickness and maintenance of bone mineralisation density at the pelvis, as opposed to a restoration of bone mineralisation mass at the hip spine and a depleting pelvis bone mass density. Between the two groups, the rate of non-vertebral injuries was identical. Nonetheless, the rate of clinical vertebral fractures in females who discontinued alendronate was higher than in females who continued. Similarly, in females treated with zoledronate for 6 years, expansion studies revealed that bones mineralisation thickness of the spine increased but bone mineralisation density of the pelvis stayed unchanged. Bone mineral thickness at the spinal level remained stable in females who stopped therapy after three years, while pelvic bone mineralisation density decreased approach pattern[7].

RANKE-AB (RECEPTOR ACTIVATOR OF NUCLEAR FACTOR K-B LIGAND ANTIBODY)

There's right now a single RANKL counteracting agent accessible for osteoporosis therapy, denosumab. Denosumab human-derived IgG2 counter acting agent that ties and equalise RANKL. The $t_{1/2}$ of the counteracting agent in plasma is up to 3 weeks, and denosumab is given SC twice annually. Equalising RANKL anticipates the recruitment and actuation of osteoclasts⁵. Secondly, because osteoblast stimulation and bone formation rely on components generated by osteoclasts and the bone during resorption, bone architecture is reduced. The clinical trial looked at the effects of denosumab therapy on osteoporotic females[8].

SELECTIVE OESTROGEN RECEPTOR MODULATOR

Specific estrogen receptor modifiers tie to the oestrogen receptors exactly as estrogen, nevertheless the partiality for the binding to the receptors is distinct for particular estrogen receptor modifiers and oestrogen. Specific estrogen receptor modifiers hence have some similitudes to estrogen, like assurance versus postmenopausal bone dysfunctioning and osteoporosis. Other impacts are inverse to

the impacts of estrogen. Particular estrogen receptor alterant imparts breast anticancer effects and has no or as it were negligible effects on the uterus[9].

REMODELING-BASED BONE-FORMING THERAPY

Teriparatide

Initiation of the therapy with teriparatide result in increments in bone mineralisation and density. The bone mineralisation thickness increments were more noteworthy at the lumbar spinal, which is overwhelmingly trabecular bone, greater than that at the pelvis sites[10].

Several researchers compared teriparatide to other osteoporotic medications in females and assessed breaks and safety factors as a consequence[5]. Teriparatide diminished the hazard of vertebral clinical fractures in comparison to risedronate. In osteoporotic males; the impact of teriparatide has to been explored. The bone mineralisation density increments were comparative to that of females at postmenopause and the hazard of vertebral breaks was reduced. In glucocorticoid-initiated osteoporotic patients; the impact of teriparatide has been explored in comparison to alendronate.

Bone mineralisation expanded essentially more within the teriparatide-users, with no

details about the risk of fracture reduction alongside significant vertebral fracture reduction[11].

Abaloparatide

The impact of abaloparatide compared to teriparatide and placebo therapy was explored in osteoporotic females at postmenopause; the study concluded that Abaloparatide expanded bone mineralisation density compared to placebo at all locales and confab a more noteworthy increment at the sum pelvis and femoral-neck in comparison to teriparatide. Repeated abaloparatide therapy diminished the chance of vertebral /non-vertebral fractures (86%/43% respectively), matched with control placebo therapy. The impact of abaloparatide osteoporosis in male patients is now under examination The frequency of plasma calcium concentration is lower in females exposed to abaloparatide (3.4%) than in females exposed to teriparatide (6.4%)[12].

MODELING-BASED BONE FORMING THERAPY

Frizzled receptor and LDL receptors expressed on osteoblasts receptors are considered as a ligand for Wnt-receptor. Wnt-receptor stimulation results in subcellular events leading to incitement of

the osteoblasts[6]. Actuation of this canonical Wnt leads to the transfer of β -catenin to the core of the osteoblasts taken after genetic transcription. The sclerostin (a glycoprotein) transcribed by the sclerostin gene overwhelmingly communicated by the osteocytes is a suppressor of the Wnt signalling pathway and, consequently, represses osteoblast reprogramming, multiplication and survival[10].

ROMOSOZUMAB

Romozozumab antagonises sclerostin when administered subcutaneously on monthly basis. Romozozumab SC administration leads to fast and conspicuous increments in bone mineralisation biomarkers. Despite continuous use, the elevation in bone mineralisation off inside 6 months and the biomarkers diminish to underneath pattern levels from thereon. Bone resorption markers diminish quickly upon starting therapy and remain below standard all through the treatment period[2]. The changes in bone trabecular modulation biomarkers expressed the double impact of romozozumab, incitement of bone arrangement and at the same time hindrance of bone degeneration. Histological testing analysis of osteocytes in ovariectomized laboratory rats/male

monkeys exposed to romozozumab illustrated expanded bone generated on trabecular/non-trabecular surfaces, in expansion to a diminished resorption[13].

COMBINATION THERAPY

A few medications are accessible for osteoporosis, and so, a yet bigger number of combinations of treatments are conceivable. Combined effects of distinctive synergistic effects have been determined, but initially with baffling comes about[13].

No studies examined the impact on fractures, but overall, the information doesn't propose a useful impact of the combination of teriparatide and an oral anti-resorptive therapy in comparison to teriparatide therapy alone [8]. The impact of additive therapy of teriparatide with a less regularly used IV bisphosphonate was explored in a study conducted on (5-mg zoledronate + teriparatide/day, for 52 weeks)[14]. Bone mineralisation thickness elevated in all three bunches. In any case, the elevation in spinal bone mineralisation density was comparative within the combined and teriparatide bunch and greater in the zoledronate bunch, while the elevation in pelvis bone mineralisation density was comparative within the zoledronate and combination bunch and

greater than within the teriparatide bunch[15].

The Information study comparing 24 months of therapy with the additive of teriparatide and denosumab in a combination or monotherapy, the study concluded that combined therapy expanded bone mineralisation density more than each therapy alone[5]. The bone-mineralisation impact of teriparatide is essentially bone rebuilding based and this could in this manner at slightest possibly be influenced by denosumab inhibiting bone degeneration and rebuilding. None of these considers were fueled to examine the impact on fracture chance. The impact of abaloparatide combined with antiresorptive therapy has not been explored[16].

SEQUENTIAL TREATMENT

Bone-generating/anti-resorptive treatment

The impacts of bone-mineralisation and bimodal approach medications are reversible. Numerous clinical studies have illustrated that bone mineralisation density is reduced when teriparatide is ceased. Volunteered patients from the fracture interruption trials illustrated that the bone mineralisation density elevated amid teriparatide therapy can be advance made strides by bisphosphonate therapy after

cessation of teriparatide and that the fracture inhibition capacity was kept up[17].

Anti-resorptive therapy /anti-resorptive therapy

Medication disappointment in osteoresorption ought to be regarded in the case of 2 occurrence fractures, the critical misfortune of bone mineralisation thickness, or non-inhibition of osteogenic tissues in a patient been treated for a period longer than a year with an anti-degenerative therapy with great passivity and no auxiliary causes of bone deficiency or break [18][19]

Anti-resorptive treatment/bone-forming

The grouping of therapy materials—at slightest whilst it relates to bone mineralisation thickness reaction to the drug regimen. The pickup in bone mineralisation thickness in reaction to teriparatide is bigger in drug-free sufferers compared to sufferers already bisphosphonates-users [19]. Nevertheless, in clinical trials, most sufferers don't have the choice of bone generation treatment as initiation therapy [20].

Bone mineralisation density increments with teriparatide after anti-degenerative therapy are reduced. The influence leans on the classes of anti degenerative therapy.

Investigations have revealed better bone mineralisation density increments in sufferers previously exposed to non-bisphosphonates (raloxifene) or exposed to bisphosphonates with a lower fondness for hydroxyapatite (risedronate) compared to those with greater affinity (alendronate) [8]. A few studies have appeared a transitory reduction in pelvis bone mineralisation density when switching from alendronate to teriparatide [21].

Switching therapy from denosumab for 24 months to teriparatide results in increments in bone degeneration, increment in spinal bone mineralisation thickness, but a marked although transitory diminish in pelvis bone mineralisation density[7]. Unfortunately, the study scarcity any anti-fracture data. This proposal is dependent on the result of the teriparatide and denosumab combined therapy uncovered bone mineralisation density reaction similar to teriparatide alone [11].

LONG-TERM MANAGEMENT OF OSTEOPOROSIS

Figure 1 outlines the prolonged use of drugs in osteoporosis. In individuals with recently confirmed osteoporosis, the starting therapy will in many patients be an anti-mineralisation therapy [22]. Nevertheless, in individuals with extreme osteoporosis, bone-mineralisation or bimodal therapy should be contemplated as a gold standard therapy on first occasion [11]. Adherence to oral bisphosphonates therapy could be difficult; however, it could be resolved with instruction of the patients and integration between the understanding and the wellbeing care framework amid the treatment. Measurements of bone generation biomarkers will offer assistance evaluate compliance but have not greatly been illustrated to augment acquiescence over examining the illness and treatment with the quiet. Patients therapy with bisphosphonates may be assessed for the fittingness of treatment cessation when treated for few years with oral or IV bisphosphonates[10].




Figure 1. Schematic presentation of long-term management of osteoporosis[22].

Biphosphonate discontinuation therapy should not be issued in patients with pelvis bone mineralisation density T score < -2.5, predominant vertebral/non-vertebral fractures during treatment. A few prescribe cessation for a fixed length of 2 years depending on the non-vertebral breaks; a few prescribe observing with bone mineralisation biomarkers and resume therapy when the biomarkers are no more declined. Whereas others prescribe advice follow-up bone mineralisation density and when a critical bone mineralisation density misfortune happens treatment is initiated again. Eventually, most concur that unused main osteoporotic breaks would be a sign for re-initiating therapy[11].

CONCLUSION

There are currently numerous neglected requirements within the treatments of osteoporosis, counting managements of serious osteoporosis, treatment of sufferers a thigh break hazard and prolong compliance to the management plan. The bone-mineralisation and multimodal therapy may offer assistance address these neglected needs. Two clinical studies have declared the priority medications that invigorate bone mineralisation over anti-degeneration in individuals with serious osteoporosis, providing evidence that a more satisfied and individualisation approaches to be used for the treatment of osteoporosis which incorporates the utilize of bone-mineralisation treatments in

subjects with extreme osteoporosis may offer assistance characterise the currently unfulfilled needs.

ACKNOWLEDGMENT

The authors are very grateful to the University of Mosul /College of Pharmacy for their provided facilities, which helped to improve the quality of this work.

REFERENCES

- [1] B. Abrahamsen, P. Eiken, D. Prieto-Alhambra, and R. Eastell, "Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: Nationwide cohort and nested case-control study," *BMJ*, vol. 353, 2016, doi: 10.1136/bmj.i3365.
- [2] J. D. Adachi *et al.*, "Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trial," *Arthritis Rheum.*, vol. 44, no. 1, pp. 202–211, 2001, doi: 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W.
- [3] S. P. H. Alexander *et al.*, "THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors," *Br. J. Pharmacol.*, vol. 176, no. S1, pp. S21–S141, 2019, doi: 10.1111/bph.14748.
- [4] E. B. Andrews *et al.*, "The US postmarketing surveillance study of adult osteosarcoma and teriparatide: Study design and findings from the first 7 years," *J. Bone Miner. Res.*, vol. 27, no. 12, pp. 2429–2437, 2012, doi: 10.1002/jbmr.1768.
- [5] G. J. Atkins and D. M. Findlay, "Osteocyte regulation of bone mineral: A little give and take," *Osteoporos. Int.*, vol. 23, no. 8, pp. 2067–2079, 2012, doi: 10.1007/s00198-012-1915-z.
- [6] R. Baron and G. Rawadi, "Minireview: Targeting the Wnt/ β -catenin pathway to regulate bone formation in the adult skeleton," *Endocrinology*, vol. 148, no. 6, pp. 2635–2643, 2007, doi: 10.1210/en.2007-0270.

- [7] G. Hattersley, T. Dean, B. A. Corbin, H. Bahar, and T. J. Gardella, "Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling," *Endocrinology*, vol. 157, no. 1, pp. 141–149, 2016, doi: 10.1210/en.2015-1726.
- [8] P. Barrionuevo *et al.*, "Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: A network meta-analysis," *J. Clin. Endocrinol. Metab.*, vol. 104, no. 5, pp. 1623–1630, 2019, doi: 10.1210/jc.2019-00192.
- [9] D. C. Bauer *et al.*, "Fracture prediction after discontinuation of 4 to 5 years of Alendronate therapy: The FLEX study," *JAMA Intern. Med.*, vol. 174, no. 7, pp. 1126–1134, 2014, doi: 10.1001/jamainternmed.2014.1232.
- [10] D. M. Black *et al.*, "Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures," *Lancet*, vol. 348, no. 9041, pp. 1535–1541, 1996, doi: 10.1016/S0140-6736(96)07088-2.
- [11] S. Boonen *et al.*, "Effects of previous anti resorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis," *J. Clin. Endocrinol. Metab.*, vol. 93, no. 3, pp. 852–860, 2008, doi: 10.1210/jc.2007-0711.
- [12] C. S. Kado DM, Browner WS, Palermo L, Nevitt MC, Genant HK, "Vertebral Fractures and Mortality in Older Women: A prospective study," vol. 159, pp. 1215–1220, 2015.
- [13] J. M. Kaufman *et al.*, "Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.," *Osteoporos. Int.*, vol. 16, no. 5, pp. 510–516, 2005, doi: 10.1007/s00198-004-1713-3.
- [14] D. Padhi, G. Jang, B. Stouch, L. Fang, and E. Posvar, "Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody," *J. Bone Miner. Res.*, vol. 26, no. 1, pp. 19–26, 2011, doi: 10.1002/jbmr.173.
- [15] R. L. Van Bezooijen *et al.*, "Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, but Not a Classical BMP Antagonist," *J. Exp. Med.*, vol. 199, no. 6, pp. 805–814, 2004, doi: 10.1084/jem.20031454.

- [16] M. D. Walker *et al.*, “Combination therapy with risedronate and teriparatide in male osteoporosis,” *Endocrine*, vol. 44, no. 1, pp. 237–246, 2013, doi: 10.1007/s12020-012-9819-4.
- [17] P. Peitsaro, B. Johansson, and S. Syrjänen, “Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique,” *J. Clin. Microbiol.*, vol. 40, no. 3, pp. 886–891, 2002, doi: 10.1128/JCM.40.3.886-891.2002.
- [18] H. Johansson *et al.*, “Imminent risk of fracture after fracture,” *Osteoporos. Int.*, vol. 28, no. 3, pp. 775–780, 2017, doi: 10.1007/s00198-016-3868-0.
- [19] K. E. Naylor *et al.*, “Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density,” *Osteoporos. Int.*, vol. 29, no. 6, pp. 1407–1417, 2018, doi: 10.1007/s00198-018-4460-6.
- [20] P. D. Miller *et al.*, “Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis a randomized clinical trial,” *JAMA - J. Am. Med. Assoc.*, vol. 316, no. 7, pp. 722–733, 2016, doi: 10.1001/jama.2016.11136.
- [21] A. L. Brotherton, “Metrics of Antimicrobial Stewardship Program Antibiotic use Stewardship metrics Benchmarking,” *Med. Clin. NA*, 2018, doi: 10.1016/j.mcna.2018.05.008.
- [22] B. L. Langdahl, “Overview of treatment approaches to osteoporosis,” *Br. J. Pharmacol.*, vol. 178, no. 9, pp. 1891–1906, 2021, doi: 10.1111/bph.15024.